## Vanda Markovic-Pekovic

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1899036/vanda-markovic-pekovic-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39	877	20	29
papers	citations	h-index	g-index
43 ext. papers	1,191 ext. citations	<b>2.9</b> avg, IF	3.5 L-index

#	Paper	IF	Citations
39	First experiences with the use of targeted and immunotherapy in the treatment of cutaneous melanoma: A single centre experience. <i>Scripta Medica</i> , <b>2022</b> , 53, 29-35	0.3	
38	Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. <i>BioMed Research International</i> , <b>2021</b> , 2021, 9996193	3	2
37	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2021</b> , 21, 527-540	2.2	11
36	Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. <i>Life</i> , <b>2021</b> , 11,	3	23
35	The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. <i>Frontiers in Public Health</i> , <b>2021</b> , 9, 671961	6	9
34	COVID-19, health care and self-medication issues in resource-limited settings: Findings and implications based on experiences in Ghana. <i>Advances in Human Biology</i> , <b>2021</b> , 11, 224	0.9	3
33	Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications. <i>Medicine Access Point of Care</i> , <b>2021</b> , 5, 239920262110276	0.8	3
32	Progress on the national action plan of Pakistan on antimicrobial resistance (AMR): a narrative review and the implications. <i>Expert Review of Anti-Infective Therapy</i> , <b>2021</b> , 1-23	5.5	7
31	Evidence-based public policy making for medicines across countries: findings and implications for the future. <i>Journal of Comparative Effectiveness Research</i> , <b>2021</b> , 10, 1019-1052	2.1	7
30	Regulation of the apothecary activity in Bosnia and Herzegovina over the Austro-Hungarian period. <i>Medicinski Glasnik</i> , <b>2021</b> , 18, 343-351	0.6	
29	Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2020</b> , 20, 1-26	2.2	33
28	The first modern pharmacy in Banja Luka: The Brammer family, three generations of pharmacists. <i>Scripta Medica</i> , <b>2020</b> , 51, 284-291	0.3	0
27	Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future. <i>Current Medical Research and Opinion</i> , <b>2020</b> , 36, 301-327	2.5	64
26	The Expiry of Humira Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 591134	5.6	21
25	Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2019</b> , 19, 251-261	2.2	19
24	Pricing of oral generic cancer medicines in 25 European countries; findings and implications. <i>GaBI Journal</i> , <b>2019</b> , 8, 49-70	3.1	20
23	The characteristics of the outpatient utilisation of medicines in the Republic of Srpska in the period 2009-2017. <i>Scripta Medica</i> , <b>2019</b> , 50, 167-176	0.3	

## (2012-2018)

22	Albania and future implications across countries. <i>Journal of Global Antimicrobial Resistance</i> , <b>2018</b> , 13, 240-245	3.4	38
21	Recent Initiatives in the Republic of Srpska to Enhance Appropriate Use of Antibiotics in Ambulatory Care; Their Influence and Implications. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 442	5.6	20
20	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. <i>Frontiers in Public Health</i> , <b>2018</b> , 6, 328	6	68
19	Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 942	5.6	43
18	The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. <i>Pharmacoeconomics</i> , <b>2017</b> , 35, 1271-1285	4.4	64
17	Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 497	5.6	26
16	Initiatives to Reduce Nonprescription Sales and Dispensing of Antibiotics: Findings and Implications. <i>Journal of Research in Pharmacy Practice</i> , <b>2017</b> , 6, 120-125	1.3	47
15	Polypharmacy among the elderly in the Republic of Srpska: extent and implications for the future. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2016</b> , 16, 609-618	2.2	8
14	Long-term drug use and polypharmacy among the elderly population in the Republic of Srpska, Bosnia and Herzegovina. <i>Vojnosanitetski Pregled</i> , <b>2016</b> , 73, 435-41	0.1	1
13	Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 197	5.6	22
12	PayersWiews of the Changes Arising through the Possible Adoption of Adaptive Pathways. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 305	5.6	44
11	Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future. <i>GaBI Journal</i> , <b>2015</b> , 4, 125-135	3.1	8
10	Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. <i>Frontiers in Pharmacology</i> , <b>2014</b> , 5, 109	5.6	34
9	Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. <i>Frontiers in Pharmacology</i> , <b>2014</b> , 5, 106	5.6	86
8	Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. <i>Frontiers in Pharmacology</i> , <b>2013</b> , 4, 39	5.6	55
7	Outpatient utilization of systemic antibiotics in the Republic of Srpska. <i>Scripta Medica</i> , <b>2013</b> , 44, 8-13	0.3	
6	Self-medication with antibiotics in the Republic of Srpska community pharmacies: pharmacy staff behavior. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 1130-3	2.6	31
5	Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2012</b> , 12, 661-71	2.2	20

4	Essential to increase the use of generics in Europe to maintain comprehensive health care?. <i>Farmeconomia E Percorsi Terapeutici</i> , <b>2012</b> , 13, 5-20	0	20
3	Outpatient utilization of drugs acting on nervous system: a study from the Republic of Srpska, Bosnia & Herzegovina. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 177-86	2.8	9
2	Outpatient utilization of antibioticis in the Republic of Srpska, in 2007 and 2008. <i>Scripta Medica</i> , <b>2010</b> , 41, 22-28	0.3	1
1	Utilisation of cardiovascular medicines in Republic of Srpska, Bosnia and Herzegovina, 5 years study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2009</b> , 18, 320-6	2.6	8